Characterization of rare germline variants in familial multiple myeloma

. 2021 Feb 13 ; 11 (2) : 33. [epub] 20210213

Jazyk angličtina Země Spojené státy americké Médium electronic

Typ dokumentu dopisy, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/pmid33583942

Grantová podpora
11R/2019 José Carreras Leukämie-Stiftung (Deutsche José Carreras Leukämie-Stiftung)

E-zdroje Online Plný text
Odkazy

PubMed 33583942
PubMed Central PMC7882594
DOI 10.1038/s41408-021-00422-6
PII: 10.1038/s41408-021-00422-6
Knihovny.cz E-zdroje

Zobrazit více v PubMed

Kumar SK, et al. Multiple myeloma. Nat. Rev. Dis. Primers. 2017;3:17046. doi: 10.1038/nrdp.2017.46. PubMed DOI

Frank C, et al. Search for familial clustering of multiple myeloma with any cancer. Leukemia. 2016;30:627–632. doi: 10.1038/leu.2015.279. PubMed DOI

Vachon CM, et al. Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance. Blood. 2009;114:785–790. doi: 10.1182/blood-2008-12-192575. PubMed DOI PMC

Pertesi M, et al. Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma. Leukemia. 2019;33:2324–2330. doi: 10.1038/s41375-019-0452-6. PubMed DOI PMC

Waller RG, et al. Novel pedigree analysis implicates DNA repair and chromatin remodeling in multiple myeloma risk. PLoS Genet. 2018;14:e1007111. doi: 10.1371/journal.pgen.1007111. PubMed DOI PMC

Wei X, et al. Germline lysine-specific demethylase 1 (LSD1/KDM1A) mutations confer susceptibility to multiple myeloma. Cancer Res. 2018;78:2747–2759. doi: 10.1158/0008-5472.CAN-17-1900. PubMed DOI PMC

Pertesi M, et al. Genetic predisposition for multiple myeloma. Leukemia. 2020;34:697–708. doi: 10.1038/s41375-019-0703-6. PubMed DOI

Went M, et al. Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma. Nat. Commun. 2018;9:3707. doi: 10.1038/s41467-018-04989-w. PubMed DOI PMC

Blocka J, et al. Familial cancer: how to successfully recruit families for germline mutations studies? Multiple myeloma as an example. Clin. Lymphoma Myeloma Leuk. 2019;19:635–644 e632. doi: 10.1016/j.clml.2019.06.012. PubMed DOI

Walker BA, et al. Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. Blood. 2018;132:587–597. doi: 10.1182/blood-2018-03-840132. PubMed DOI PMC

Maura F, et al. Genomic landscape and chronological reconstruction of driver events in multiple myeloma. Nat. Commun. 2019;10:3835. doi: 10.1038/s41467-019-11680-1. PubMed DOI PMC

Foltz SM, et al. Evolution and structure of clinically relevant gene fusions in multiple myeloma. Nat. Commun. 2020;11:2666. doi: 10.1038/s41467-020-16434-y. PubMed DOI PMC

Rahman N. Realizing the promise of cancer predisposition genes. Nature. 2014;505:302–308. doi: 10.1038/nature12981. PubMed DOI PMC

Hu J, et al. Targeting signaling pathways in multiple myeloma: Pathogenesis and implication for treatments. Cancer Lett. 2018;414:214–221. doi: 10.1016/j.canlet.2017.11.020. PubMed DOI

Halvarsson BM, et al. Direct evidence for a polygenic etiology in familial multiple myeloma. Blood Adv. 2017;1:619–623. doi: 10.1182/bloodadvances.2016003111. PubMed DOI PMC

Najít záznam

Citační ukazatele

Možnosti archivace